生物分子模拟论坛

 找回密码
 我想注册

QQ登录

只需一步,快速开始

扫一扫,访问微社区

查看: 984|回复: 7

[研发新闻] 2012年1-10月,FDA批准的NMEs!

[复制链接]
发表于 2012-10-25 12:36:44 | 显示全部楼层 |阅读模式

马上注册,结交更多好友,下载更多分子模拟资源。

您需要 登录 才可以下载或查看,没有帐号?我想注册

x
2012年获FDA批准的NMEs如下,包括药物的商品名、批准日期、活性成分以及适应症等。

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm

No.
Drug Name
Active Ingredient
Date
What it’s used for
28.Fycompaperampanel10/22/12
To treat partial onset seizures in patients with epilepsy ages 12 years and older.
Press Release
27.Jetreaocriplasmin10/18/12
To treat an eye condition called symptomatic vitreomacular adhesion (VMA).
Press Release
26.Stivargaregorafenib9/27/12
To treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).
Press Release
25.Choline C 11 InjectionCholine C 11 Injection9/12/12
A Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.
Press Release
24.Aubagioteriflunomide9/12/12
For the treatment of adults with relapsing forms of multiple sclerosis (MS).
Press Release
23.Bosulifbosutinib9/4/12
To treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.
Press Release
22.Xtandienzalutamide8/31/12
To treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.
Press Release
21.Linzesslinaclotide8/30/12
To treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
Press Release
20.Neutrovaltbo-filgrastim8/29/12
To reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.
Press Release
19.Stribildelvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate8/27/12
A once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.
Press Release
18.Zaltrapziv-aflibercept8/3/12
For use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.
Press Release
17.Tudorza Pressairaclidinium bromide7/23/12
For the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Press Release
16.Kyprolis
carfilzomib
7/20/12
To treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory.
Press Release
15.Prepopik
sodium picosulfate, magnesium oxide and citric acid
7/17/12
To help cleanse the colon in adults preparing for colonoscopy.
Press Release
14.Myrbetriq
mirabegron
6/28/12
To treat adults with overactive bladder.
Press Release
13.Belviq
lorcaserin hydrochloride
6/27/12
For chronic weight management.
Press Release
12.Perjeta
pertuzumab
6/8/12
To treat patients with HER2-positive late-stage (metastatic) breast cancer.
Press Release
11.Elelyso
taliglucerase alfa
5/1/12
For long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder
Press Release
10.Stendra
avanafil
4/27/12
To treat erectile dysfunction.
Press Release
9.Amyvid
Florbetapir F 18
4/6/12
Used as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.
8.Omontys
peginesatide
3/27/12
To treat anemia, a condition in which the body does not have enough healthy red blood cells, in adult dialysis patients who have chronic kidney disease (CKD).
Press Release
7.Surfaxin
lucinactant
3/6/12
For the prevention of respiratory distress syndrome (RDS), a breathing disorder that affects premature infants.
Press Release
6.Zioptan
tafluprost
2/10/12
For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Press Release
5.Kalydeco
ivacaftor
1/31/12
For the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
Press Release
4.Erivedge
vismodegib
1/30/12
To treat adult patients with basal cell carcinoma, the most common type of skin cancer.
Press Release
3.Inlyta
axitinib
1/27/12
To treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
Press Release
2.Picato
ingenol mebutate
1/23/12
For the topical treatment of actinic keratosis.
1.Voraxaze
glucarpidase
1/17/12
To treat patients with toxic levels of methotrexate in their blood due to kidney failure.
Press Release

-从2002年以来,FDA平均每年批准NMEs24个,其中2002年最少17个,2004年高达36个,而今年有28个,与去年相当(PS:27)
在美国,申请新药流程大概是首先向FDA提交一份NDA,包括化学组成、生产工艺、动物和人体试验数据等,然后CDER审评,最后FDA panels批准是否获批。此过程,中国与其相似。

评分

参与人数 1金币 +5 收起 理由
川大-灰太狼 + 5 赞一个!

查看全部评分

发表于 2012-10-25 16:24:15 | 显示全部楼层
这个太有用了,尤其对国内搞模仿创新的公司
发表于 2012-10-25 18:17:16 | 显示全部楼层
另外,如果能找到上市药的专利过期时间总结,对于仿制药的选取应该会有较好的指引。要是谁有这方面资料共享下吧。
发表于 2012-10-26 08:58:15 | 显示全部楼层
现在做仿创还是可以的,纯粹的仿制药个人感觉没有前途了
发表于 2012-10-26 13:22:01 | 显示全部楼层
本帖最后由 中科院-石头 于 2012-10-26 13:25 编辑

赞同你的观点,我知道的仿制创新成功的有两个例子,一个是浙江贝达药业的Icotinib(如下图),另一个是郭宗儒的艾瑞昔布。Icotinib由原先阿斯利康的Erlotinib经过6,7位亲水链的环合,有效的规避专利的保护。其实,这里我之前也有个困惑的地方,这种me-too药物的研发(尤其是小改动)似乎对学术并没有多大贡献,仅仅是为了突破专利,降低风险和经济利益。这也许是面对国内药物研发现状所选择的一条妥协道路,正如郭宗儒所提倡的“仿制创新”概念一样。反观国外一些大学和公司的药物研发,往往是在庞大的生物医学知识基础下,或筛选,或设计,得到全新化合物的药物,反过来利用这些化合物促进生命科学的研究和治疗疾病。扯远一点说,前者是技术,后者是科学。

untitled~1.jpg

评分

参与人数 1金币 +3 收起 理由
川大-灰太狼 + 3 非常好的讨论!

查看全部评分

发表于 2012-10-26 13:28:48 | 显示全部楼层
浙江贝达药业的Icotinib其实不是他们研发的,是老板所在国外公司筛选化合物中的一个,只是性质比另外一个药差就没有申报专利,他们运气特别好。
全新药物研发涉及到的领域太广,中国目前没有这样的综合实力。做企业首先要生存,才能有力量研发,仿创算是一种既适合国内研发实力又能给企业一些生存希望的平衡模式。

评分

参与人数 1金币 +1 收起 理由
川大-灰太狼 + 1 呵呵 侧面消息

查看全部评分

 楼主| 发表于 2012-10-26 17:18:54 | 显示全部楼层

十二五之后国家重视了有中国特色的新药研发,期望能有不错的未来。。。。。。
发表于 2012-11-6 16:17:52 | 显示全部楼层
但是国家还是很鼓励仿制药的,特别是能产业化的,之前发改委还搞了个通用名药物的专项,每个项目都上千万的资助额。
您需要登录后才可以回帖 登录 | 我想注册

本版积分规则

QQ|分迪科技|小黑屋|手机版|Archiver|生物分子模拟论坛 ( 蜀ICP备14009200号-3 )

GMT+8, 2019-10-23 12:55 , Processed in 0.082915 second(s), 26 queries .

Powered by Discuz! X3.4

© 2001-2017 Comsenz Inc.

快速回复 返回顶部 返回列表